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Background: Genome-wide association studies (GWAS) have provided a large set of genetic loci influencing the risk
for many common diseases. Association studies typically analyze one specific trait in single populations in an isolated
fashion without taking into account the potential phenotypic and genetic correlation between traits. However, GWA
data can be efficiently used to identify overlapping loci with analogous or contrasting effects on different diseases.
Results: Here, we describe a new approach to systematically prioritize and interpret available GWA data. We focus on
the analysis of joint and disjoint genetic determinants across diseases. Using network analysis, we show that variant-
based approaches are superior to locus-based analyses. In addition, we provide a prioritization of disease loci based on
network properties and discuss the roles of hub loci across several diseases. We demonstrate that, in general, agonistic
associations appear to reflect current disease classifications, and present the potential use of effect sizes in refining and
revising these agonistic signals. We further identify potential branching points in disease etiologies based on
antagonistic variants and describe plausible small-scale models of the underlying molecular switches.
Conclusions: The observation that a surprisingly high fraction (>15%) of the SNPs considered in our study are
associated both agonistically and antagonistically with related as well as unrelated disorders indicates that the
molecular mechanisms influencing causes and progress of human diseases are in part interrelated. Genetic overlaps
between two diseases also suggest the importance of the affected entities in the specific pathogenic pathways and
should be investigated further.
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reproduction in any medium, provided the or[1]. In contrast to few single loci exerting large effects on
some phenotypes – mostly immune-related traits – the
majority of traits was only associated with loci displaying
small effects of odds ratios ranging from 1.1 to 1.5 [2].
Meta-analyses of several GWA studies further extended
the set of known disease-related associations with even
lower-effect variants. Despite the impressive progress in
the field, for most traits only a small proportion of the
total heritability is yet explained by known risk variants
[3]. A notable exception is type 1 diabetes (T1D) where
validated risk loci explain a large proportion of the total
heritability [4]. In contrast, for most traits a considerably
larger number of variants was reported to be associated,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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itability [5].
Intriguingly, although published individual GWAS are
usually carried out for one trait at a time, a significantFigure 1 Illustration of the different disease networks based on geno
all association data. The two disjoint node sets are diseases (n = 111) and lo
other by an edge if a variant (n = 1,120) within the respective locus is assoc
consisting of 84 traits and 157 loci, retrieved by removing isolated traits an
variant network) that corresponds to a variant-based representation of the
comprising associations with this and at least one other trait. The network
diseases (see also Additional file 2: Table S1). The colors of the disease nod
multi-colored nodes indicate an association with different disease classes; l
reflects the number of loci a disease is associated with. In C, the edge colo
corresponds to antagonistic variant(s), and blue mark both agonistic and aoverlap in the associations of several complex diseases
becomes apparent [6]. Besides effects on a specific
phenotype, loci and single SNPs thus may also exert
pleiotropic effects by contributing to a variety of traits.me-wide association data. A: The bipartite graph constructed from
ci (n = 734; 508 gene loci and 226 intergenic loci), connected to each
iated with the corresponding trait. B: The SLN (shared locus network)
d loci that are associated with a single trait only. C: The SVN (shared
data. Here, a trait and a locus are linked if the locus contains a variant
consists of 175 SNPs located in 94 loci that are associated with 55
es correspond to disease classes according to the MeSH ontology,
oci are depicted as transparent, diamond-shaped nodes. The node size
r reflects the allelic information: gray indicates agonistic variant(s), red
ntagonistic signals.
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closely related traits should be shared, multi-functionality
of a gene in phenotype presentation, i.e. pleiotropy,
sensu stricto refers to seemingly unrelated and distinct
traits [7]. Loci or variants affecting several traits might
have small effects on each specific trait, but may be of
major biological interest while indicating shared or
branching etiological mechanisms. In principle, the in-
fluence of such loci can be agonistic or antagonistic, i.e.
involve concurrent similar or opposite effects of the same
variant for different traits. So far, few studies attempted to
study such loci in a systemic fashion and rather focused
on shared risk variants in closely related traits like
autoimmune diseases [8-10], heart diseases [11] or cancer
[12].
In order to identify shared or branching pathways of
related as well as diverse (i.e. medically and pheno-
typically distinct) diseases, we performed a systematic
comparative analysis of genetic commonalities and dif-
ferences across traditionally defined traits using the
available repository of GWAS results. In the context of
network medicine [13], we utilized an approach based
on the diseasome concept [14] and investigated high-Figure 2 LD based locus assignment and its error sources. At the exam
6 exemplary SNPs (blue box). LD information is given by a color scale displ
and white no LD. Example SNPs in LD are connected with black dashed lin
assignment are given. An assignment error I occurs if two variants not in L
intergenic region or gene desert and thus are assigned the same locus. He
The consequence of this type of error is a shared association on the locus
introduced if two variants are in LD but diverge in their assigned locus. He
LD data the link between both variants is lost if only the locus level is conssignificance associations beyond conventional single-
marker analysis in a hypothesis-free and comprehensive
way. In former studies we found differing approaches of
gene and locus assignment to association markers which
partially led to controversial results (e.g. [15]). We there-
fore developed a more sophisticated locus assignment
method and evaluate its reliability by utilizing the infor-
mation contained directly in the reported markers. For
this variant-based approach we manually curated a high-
quality data set to construct a network extending the
knowledge on genetic overlaps between diseases as pro-
vided by GWA studies.Results and discussion
Considerable discrepancies across GWAS through differ-
ing genotyping platforms, varying sample sizes and diver-
ging measures of statistical significance demand accurate
data selection. Therefore, to sustain the genuine variant-
linked information provided by GWAS, we combined
several steps of data curation and filtering. To provide a
comprehensive base for the analysis of potentially multi-
functional loci and variants, respectively, we compiled twople of chromosome 8q21.11, LD-based locus assignment is given for
aying the LD-measure r2 with red depicting strong LD, blue low LD
es. In the gray boxes, the two error sources of automated locus
D, i.e. in two independent LD blocks, are located in the same gene,
re, this is the case for the variants rs-A/rs-B and rs-E/rs-F, respectively.
level not mirrored on the variant level. An assignment error II is
re, this is the case for rs-C and rs-D. Due to such abnormalities in the
idered.
Arnold et al. BMC Genomics 2012, 13:490 Page 4 of 15
http://www.biomedcentral.com/1471-2164/13/490network representations of the information made available
by GWA studies: the locus-based “shared locus network”
(SLN, Figure 1B) and the variant-based “shared variant
network” (SVN, Figure 1C). To be able to cluster diseases
by their “genetic relatedness”, we additionally created a
disease-centric projection of the SVN (Additional file 1:
Figure S1).
We defined the associated loci over the variant-based
linkage disequilibrium (LD) measure r2 and, accordingly,
expected the SLN and the SVN (Figure 1B and C) to be
of similar shape. However, when visually comparing the
networks, significant differences in size and structure be-
came apparent. Therefore, we performed further ana-
lyses to compare established property measures of the
networks in detail to investigate potential reasons for
this divergence.Table 1 Antagonistically linked traits
Disease Abbr. Anta
CROHN DISEASE CD AST (
SLE (1
ASTHMA AST CD (1
GLIOMA GLI COR
ARTHRITIS, RHEUMATOID RA AST (
MULTIPLE SCLEROSIS MS RA (2
COLITIS, ULCERATIVE UC AST (
LUNG NEOPLASMS LN PN (5
TESTICULAR NEOPLASMS TN GLI (5
VITILIGO VIT CD (1
DIABETES MELLITUS, TYPE 1 T1D CD (1
DIABETES MELLITUS, TYPE 2 T2D GLI (9
CELIAC DISEASE CeD UC (1
IDIOPATHIC PULMONARY FIBROSIS IPF GLI (5
PSORIASIS PS AST (
LUPUS ERYTHEMATOSUS, SYSTEMIC SLE CD (1
GLAUCOMA GLA GLI (9
MELANOMA MEL VIT (1
PANCREATIC NEOPLASMS PN LN (5
ALCOHOLISM ALC HNN
COLORECTAL NEOPLASMS CRC CeD
INFLAMMATORY BOWEL DISEASES IBD T1D (
CARCINOMA, HEPATOCELLULAR HCC MS (1
LIVER CIRRHOSIS, BILIARY BLC AST (
CORONARY DISEASE COR GLI (9
HEAD AND NECK NEOPLASMS HNN ALC (
Listed are diseases and the traits that share an antagonistic variant with the respec
column specifies the abbreviation of the disorder in the first column. The third colu
antagonistic link to the disorder in column one, followed by the chromosomal loca
column lists the count of traits antagonistically linked to the disorder in column onShared locus vs. shared association analysis
Despite the size difference, the SLN shows greater net-
work heterogeneity (SLN=1.30, SVN=1.17) and lower
centralization (SLN=0.175, SVN=0.205) and density
(SLN=0.014, SVN=0.021) values than the SVN. Further-
more, the intersection between the SVN and the SLN
lacks not only 5% of the nodes but also 10% of the edges
of the SVN. These numbers imply that the process of
translating LD data into locus information is at least partly
inconsistent. Analysis of the structure of the assigned LD
blocks showed two error sources in shared locus analysis
(illustrated in Figure 2). First, variants in two independent
LD blocks are assigned the same locus but are not in LD
(assignment error I). Thus, shared loci are found that are
not reflected in the variant based data. Second, if two
SNPs are in strong LD but the individual long range LDgonistically Linked Traits (Loci) #
17q12); T1D (1p13, 16p11); VIT (1p13); T2D (2p21); RA (1p13);
p13); PS (19p13); MS (17q21)
8
7q12); UC (17q12); BLC (17q12); RA (17q12); PS (5q31) 5
(9p21); T2D (9p21); GLA (9p21); IPF (5p15) ; TN (5p15) 5
17q12); MS (20q13); CD (1p13) 3
0q13); HCC (1p36); CD (17q21) 3
17q12); CeD (1p36); SLE (1q23) 3
p15); IPF (5p15); TN (5p15) 3
p15); LN (5p15) 2
p13); MEL (11q14) 2
p13, 16p11); IBD (1p13) 2
p21); CD (2p21) 2
p36); CRC (3q26) 2
p15); LN (5p15) 2
5q31); CD (19p13) 2











tive disorder. In the first column the considered disease is given. The second
mn contains the abbreviated diseases as defined in column two which have an
tion of the antagonistically associated variant(s) in parentheses. The last
e. For a more detailed listing see Additional file 2: Table S1.
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SNP covers a greater area at the given r2-threshold), an as-
signment error II occurs. In this case the two SNPs are
assigned to different loci (in the example above, this is due
to the different sizes of their LD blocks which may contain
distinct gene sets) and their LD connection is lost. These
observations suggest that (i), the SLN contains loci which
overlap between traits but the associated markers are not
in strong LD, (ii), there are several traits which are con-
nected to the SLN via a single, potentially misleading link
(as not mirrored in the variant-based data), and, (iii), even
a LD-based locus assignment is unable to identify all
shared associations (n=25 of unidentified loci, based on
the assignment error II). Due to this limited sensitivity
and specificity in detecting LD-based correlations between
the reported markers on locus scale, we used the smaller
but more accurate variant-based SVN for further analyses.
Moreover, the risk allele data in the SVN allows for the in-
clusion of the direction of the effects, i.e. agonistic and an-
tagonistic, on different traits. Diseases that share
antagonistic or agonistic, respectively, associated variants
are listed in Tables 1 and 2. Another advantage is that the
SVN can be compared to other variant-based approaches
assessing the genetic overlap between traits. Recently, a
statistic to identify SNPs with effects across phenotypes
(the cross-phenotype meta-analysis statistic, CPMA) was
proposed by Cotsapas et al. [8]. It compares the distribu-
tion of association P-values of a SNP across seven GWAS
on distinct autoimmune diseases to the exponential(1)-
distribution representing the expected decay rate of asso-
ciation P-values. As in our approach we use pre-filtered
associations, this method cannot readily be employed on
our data. However, using the data provided by Cotsapas
and colleagues on autoimmune loci in the SVN, we
retrieved CPMA P-values on 30 SNPs ( 17%) corre-
sponding to 28 loci ( 30%) in our data. The CPMA clas-
sified all SNPs as significantly effective across diseases
(P< 0.05, see Additional file 3: Table S2). Thus, we were
able to validate nearly one third of the loci contained in
the SVN by an independent approach, which underlines
the suitability of the network.
Topology of the SVN
Its degree distribution attributes the SVN a scale-free
network, i.e. it approximates a power-law (P(k) k−γ; γ=
1.32;R2 = 0.69) (Additional file 4: Figure S2). Interest-
ingly, also when considering the two node types separ-
ately, disease nodes (γ= 0.97;R2 = 0.71) as well as locus
nodes (γ= 2.98;R2 = 0.93) show scale-free degree distri-
butions (Additional file 4: Figure S2). The scale-free
property classifies the network (and its two sets of node
types, respectively) as structured, i.e. non-random [13].
It has to be considered that the limited size of the SVN
leads to inaccuracies in distribution fitting and thusreduces the explanatory value of this observation. How-
ever, as clinically related diseases (i.e. diseases which
present similar symptoms) should present a higher gen-
etic overlap than unrelated disorders, this finding meets
expectations.
The variant-based SVN also shows no artificial charac-
ter with regards to its topology. Both locus and disease
node sets comprise hubs, here defined as nodes with a
degree >3, which form the central elements in the net-
work. As in each GWAS multiple markers are associated
with a single disease, one would expect hubs to be con-
stituted mostly of disease nodes. In line with that, 74%
of the hubs in our network are disease nodes. The
remaining 26% are loci hubs (seven gene loci and three
intergenic loci). Several of these loci have been previ-
ously identified as influencing susceptibility to multiple
diseases like the HLA region on chromosome 6 [16], a
cancer locus at chromosome 8q24 [12], and a coronary
artery disease locus at chromosome 9p21 [11]. Further
hub loci are PTPN22, a known player across several
autoimmunity disorders [17], and IL23R, which has been
shown to direct inflammatory processes [18]. In
addition, we observed hubs which have not yet been
described as predisposing to a whole group of diseases,
such as TNPO3 which appears to predispose to various
autoimmune diseases like systemic lupus erythematosus,
systemic scleroderma, and rheumatoid arthritis [19-21],
or TNFSF15, which shows associations with several in-
flammatory diseases [22-25]. As expected, in the major-
ity of cases the traits linked to one hub can be assigned
to the same disease group and, further, diseases which
are not obviously related to other disorders linked to the
respective hub are mostly associated with antagonistic
signals. For instance, in a four-gene locus at chromo-
some 17q12 (GSDML/IKZF3/ORMDL3/ZPBP2, see
Additional file 2: Table S1), four autoimmune diseases
are associated with the same risk allele that in turn has
opposite effects on asthma [20,25-27]. Thus, our results
indicate that loci associated with several diseases have
an effect specific to a certain disease group rather than
effects on unrelated diseases, and that, if there is an ef-
fect on an unrelated disease, it can often be distin-
guished by the direction of the effect.
Disease clustering mirrors trait relatedness
To identify shared and branching mechanisms we split
the SNP association data into agonistic and antagonistic
variants. Since in most cases there is no solid and com-
prehensive basis of experimental data that would allow
for a more sensitive classification, we suggest that the
best available indication of distinct effects of a variant on
two diseases is the signal itself being different. There-
fore, we define a SNP to be agonistic if all disorders are
associated with the same risk allele of the SNP.
Table 2 Agonistically linked traits
Disease Abbr. Agonistically Linked Traits (Loci) #
CROHN DISEASE CD UC (1p31, 1q32, 3p21, 5p13, 9p24, 9q32, 9q34, 10q24,
21q21, 21q22); IBD (1p31, 9q32, 10q22, 16q12, 20q13, 22q12);
CeD (2q12, 18p11, 22q11); LEP (9q32, 13q14); MG (22q12);
T1D (1q32, 18p11); SC (3p21); OVARIAN NEOPLASMS (8q24);
AS (1p31); LL (2q37); HTG (2p23); AA (11q13); MS (10p15); AD (11q13)
14
ARTHRITIS, RHEUMATOID RA CeD (1p36, 4q27, 6q23); SLE (2q32, 7q32, 8p23); T1D (2q33, 4p15, 21q22);
BLC (7q32); SS (7q32); FL (6p21); UC (6q23); LBL (6p21);
SCHIZOPHRENIA (6p21); VIT (21q22)
10
CELIAC DISEASE CeD CD (2q12, 18p11, 22q11); RA (1p36, 4q27, 6q23); UC (2p16, 6q23);
T1D (18p11); BLC (7p14); VIT (3q28); HYP (12q24); SLE (6p21); MG (6p21)
9
COLITIS, ULCERATIVE UC CD (1p31, 1q32, 3p21, 5p13, 9p24, 9q32, 9q34, 10q24, 21q21, 21q22);
CeD (2p16, 6q23); AS (1p31, 2q11); IBD (1p31, 21q22); SC (3p21); PS (1p31);
RA (6q23); T1D (1q32); SLE (7q32)
9
CORONARY DISEASE COR MCI (1p13, 1p32, 1q41, 2q33, 6p24, 9p21, 10q11, 19p13, 21q22);
CAD (1p13, 3q22, 9p21); ICA (10q24); PD (10q24); AAA (9p21);




SLE RA (2q32, 7q32, 8p23); SS (2q32, 7q32); LN (6p21); BLC (7q32);




T1D RA (2q33, 4p15, 21q22); CD (2q33, 4p15, 21q22); CeD (18p11);
AA (12q13); VIT (21q22); UC (1q32)
6
HYPERTENSION HYP ICA (10q24); PD (10q24); COR (10q24); KIDNEY FAILURE,




IBD CD (1p31, 9q32, 10q22, 16q12, 20q13, 22q12); LEP (9q32);
UC (1p31, 21q22); MG (22q12); AS (1p31)
5
LIVER CIRRHOSIS, BILIARY BLC RA (7q32); SLE (7q32); SS (7q32); MS (12p13); CeD (7p14) 5
CORONARY ARTERY
DISEASE
CAD COR (1p13, 3q22, 9p21); MCI (1p13, 9p21); AAA (9p21); T2D (2q36) 4
GLOMERULONEPHRITIS,
MEMBRANOUS
MG IBD (22q12); CD (22q12); SLE (6p21); CeD (6p21) 4
AORTIC ANEURYSM,
ABDOMINAL
AAA COR (9p21); CAD (9p21); MCI (9p21) 3
INTRACRANIAL ANEURYSM ICA PD (10q24); HYP (10q24); COR (10q24) 3
LUNG NEOPLASMS LN SLE (6p21); COPD (15q25); PVD (15q25) 3
LYMPHOMA, FOLLICULAR FL LBL (11q24); RA (6p21); LL (6p21) 3
MYOCARDIAL INFARCTION MCI COR (1p13, 1p32, 1q41, 2q33, 6p24, 9p21, 10q11, 19p13, 21q22);
CAD (1p13, 9p21); AAA (9p21)
3
PARKINSON DISEASE PD HYP (10q24); COR (10q24); ICA (10q24) 3
SCLERODERMA, SYSTEMIC SS SLE (2q32, 7q32); RA (7q32); BLC (7q32) 3
SPONDYLITIS, ANKYLOSING AS UC (1p31, 2q11); IBD (1p31); CD (1p31) 3
VITILIGO VIT CeD (3q28); RA (21q22); T1D (21q22) 3
ALOPECIA AREATA AA T1D (12q13); CD (11q13) 2
CHOLANGITIS, SCLEROSING SC UC (3q21); CD (3q21) 2
DERMATITIS, ATOPIC AD GLIOMA (20q13); CD (11q13) 2
DIABETES MELLITUS, TYPE 2 T2D OBESITY (16q12); CAD (2q36) 2
HEAD AND NECK NEOPLASMS HNN GASTROINTESTINAL NEOPLASMS (10q23);
ALCOHOLISM (12q24)
2
HYPERTRIGLYCERIDEMIA HTG CD (2p23); COR (11q23) 2
LEPROSY LEP CD (9q32, 13q14); IBD (9q32) 2
LEUKEMIA, LYMPHOID LL CD (2q27); FL (11q24) 2
LYMPHOMA, LARGE B-CELL,
DIFFUSE
LBL FL (6q21); RA (6q21) 2
MULTIPLE SCLEROSIS MS CD (10p15); BLC (12p13) 2
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Table 2 Agonistically linked traits (Continued)
PERIPHERAL VASCULAR
DISEASES
PVD COPD (15q25); LN (15q25) 2
PROSTATIC NEOPLASMS PRN COLORECTAL NEOPLASMS (8q24); ENDOMETRIAL NEOPLASMS (17q12) 2
PSORIASIS PS UC (1p31); ARTHRITIS, PSORIATIC (6q21) 2
PULMONARY DISEASE,
CHRONIC OBSTRUCTIVE
COPD LN (15q25); PVD (15q25) 2
Listed are diseases that share agonistic associations with at least two traits. In the first column the considered disease is given. The second column specifies the
abbreviation of the disorder in the first column. The third column contains the disease abbreviations (as defined in column two) of traits which have an agonistic
link to the disorder in column one, followed by the chromosomal location of the agonistically associated variant(s) in parentheses. Here, the full MeSH term is
given for traits for which no abbreviation was defined. The last column lists the count of traits agonistically linked to the disorder in column one. For the
complete list of agonistically linked traits and more details see Additional file 2: Table S1.
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http://www.biomedcentral.com/1471-2164/13/490Conversely, we consider a SNP antagonistic if the asso-
ciated risk alleles differ between diseases. Accordingly, in
the analysis of genetic overlaps as a measure of trait
similarity only agonistic variants were included.
As similar diseases are more likely to share associa-
tions than diseases in distinct classes, we expected the
SVN to be organized in a modular fashion. This was
confirmed by the decrease of the degree distribution of
the topological coefficient with the number of links per
node (Additional file 4: Figure S2). To retrieve these
modules, we applied a hierarchical clustering approach.
The SVN contains two node types (loci and traits). As
we wanted to directly assess variant-based disease re-
latedness, we used its disease centric projection for hier-
archical correlation clustering. For data normalization,
we calculated the Pearson correlation coefficient (PCC)
for all pairs of diseases based on their genetic agonistic
overlap with all other diseases. The clustering returned
15 disease clusters (Figure 3) and six diseases which
show no or only weak correlation with any other disease.
With the exception of the heterogeneous cluster 5
(hypertriglyceridemia, ovarian neoplasms, lymphoid
leukemia, atopic dermatitis), the clusters mostly contain
related diseases. However, many clusters also contain
traits unrelated to the other phenotypes like schizophre-
nia in the autoimmune cluster 2. This indicates that
clinical disease classifications appear to be reflected on
the genetic level in general. Notably, several small clus-
ters contain diseases which are either linked through
common environmental risk factors – like smoking for
lung neoplasms, peripheral vascular diseases, and
chronic obstructive pulmonary disease – or present high
frequencies of comorbidity, e.g. type 2 diabetes (T2D)
and obesity. To get an insight into the overall extent of
reported comorbidities of the diseases within the 15
clusters, we used publicly available resources [28,29] and
literature mining. The within-cluster fraction of disease
co-occurrence ranged from 75% to 100% (μ= 95.89%,
σ= 8.66%) which provides empirical evidence of the
interrelation of diseases clustered together by genetic in-
formation. Such clusters containing diseases that presenthigh ratios of comorbidity may be potential artifacts due
to “contaminated” disease cohorts including a substan-
tial number of comorbid cases. The unbiased search for
the relation of a trait marker to a disease phenotype as
performed in GWAS does not distinguish between mar-
kers for a primary or related secondary (comorbid) dis-
ease. Our results suggest that this aspect may have been
underestimated in some studies, albeit the presence of
independently shared etiological mechanisms can natur-
ally not be ruled out in general.
Overall, the outcome of the clustering poses the ques-
tion of the extent of the influence of phenotype classifi-
cation and population stratification on GWAS results.
Frequent comorbidities (also of seemingly unrelated dis-
eases such as obesity and cancer [30]), diagnostic diffi-
culties in highly related diseases like Crohn’s disease
(CD) and ulcerative colitis (UC) [31], and structural
(genetic) differences in population subgroups are known
to complicate GWAS and impact their outcomes [32].
With growing sample sizes in case–control studies, the
potential of false positives produced by such phenomena
also increases. As a response, manifold control proce-
dures to handle these and other confounding factors
have been developed which are widely used and well
appreciated [32]. The heterogeneity of the clusters we
retrieved once more highlights the need for the develop-
ment and application of such methods.
Odds ratio as potential indicator of primary effects
In the context of agonistic association overlap between
related diseases, we used the odds ratios (ORs) reported
with the SNPs to investigate their impact on the respect-
ive traits. In general, the highest ORs are reported for
associations of autoimmune diseases to the HLA locus
on chromosome 6. Associations with traits where few
gene variants with strong effects are reported, e.g.
rs6107516 in the prion protein PRNP associated with
Creutzfeldt-Jakob disease (OR= 38.5) or rs2071348 in
the hemoglobin gene cluster at 11p15.4 associated with
beta-thalassemia (OR= 4.33), are exceptions from the
majority of associations displaying small ORs [33,34].
Figure 3 Clustering of diseases with respect to genetic signals. We applied complete-linkage hierarchical clustering to identify groups of
traits which show homogeneous patterns of genetic overlap to other disorders. We calculated for each pair of diseases the Pearson correlation of
the patterns of overlap to the other diseases. The correlation values are ranging from −1 (white) indicating complete negative correlation to +1
(black) reflecting a perfect positive correlation. As the minimal value of the correlation coefficient was >−0.1, we collapsed the range of negative
correlation. In red numbers, the 15 disease clusters are denoted. The Euclidian distance threshold was chosen as the maximal distance at which
the six diseases showing no or only weak correlation with any other disease (disease names in gray) remain non-clustered.
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http://www.biomedcentral.com/1471-2164/13/490Based on the effect size of variants associated with more
than one trait and the same risk allele, we identified
three patterns.
First, we identified variants which are likely to
present general agonistic risk factors for a group of
related diseases or syndromes such as rs13015714 in
an interleukine receptor gene cluster at chromosome
2q12.1. This SNP is associated with celiac disease
(CeD) and Crohn’s disease (CD) with equal ORs (OR=1.19) [24,35]. In cases of frequent comorbidities,
though, comparable ORs have limited informative
value. The SNP rs9939609 in the FTO gene for in-
stance is associated with T2D and obesity with nearly
equal ORs (OR= 1.34 and OR= 1.32) and thus appears
to link two coequal traits of the metabolic syndrome
(we refer to the definition of the International Diabetes
Foundation, 2006) [36,37]. However, for SNPs in the
FTO gene it has been shown that adjustment for body
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of the association with T2D [38].
Second, SNPs appeared in several cases to be primarily
associated with one disease, which in turn represents a
risk factor for another associated trait. For instance,
rs2200733 on chromosome 4q25 is linked to atrial fibrilla-
tion with a higher OR (OR=1.72) than to stroke (OR=
1.26) [39,40]. Another example is rs964184 which is
located proximal to the apolipoprotein gene cluster on
chromosome 11q23 which is associated with hypertrigly-
ceridemia with a markedly higher OR (OR=3.28) than to
coronary disease (OR=1.13) [41,42]. The lower effects of
the markers on the hypothesized “secondary sequels” may
be explained by the fact that these are caused by the pri-
mary diseases, but with less than 100% penetrance.
Third, we speculate that the OR might allow conclu-
sions with respect to the evaluation of an association in
cases where similar traits are linked to the same SNP
with diverging effect sizes. For instance, CD and ulcera-
tive colitis (UC) share multiple risk loci. The two dis-
eases are strongly related in their etiology and pathology.
Thus, a clinical distinction of both diseases is difficult if
based only on few criteria and might lead to inaccurate
case ascertainment leading to mixed associations [31].
However, for several SNPs such as rs11209026, which is
located in the IL23R gene, we found notably higher
effects on CD (OR= 3.84) than on UC (OR= 1.74)
[25,43]. Conversely, rs3024505 which lies proximal to
the IL10 gene shows a greater effect on UC (OR= 1.46)
than on CD (OR= 1.12) [24,44]. Interestingly, it has been
shown that IL23 is selectively upregulated in CD while
levels in UC patients are normal and IL10 expression
appears to be higher in UC as compared to CD [24,45].
Thus, the OR might – similar to the above examples –
allow for identifying potentially misleading associations
in closely related diseases which may result from diag-
nostic errors.
Identification of branching etiologies
We searched for evidence that antagonistic signals rep-
resent genetic indicators of branching points in the eti-
ologies of two diseases or disease groups. For the
assessment of potentially multifunctional variants we
therefore focused on markers with inverse effects. We
identified 44 such variants, which represent almost 4%
of the original association data analyzed and about 25%
of the SNPs associated with more than one disease. Of
those 44 variants, about one fifth (n = 9) are located in
the HLA region. SNP-markers in that region are known
to differ in their ability to capture the classical HLA-
alleles [46] and therefore were not considered further for
the present analysis.
For cases where the function of the harboring genes is
known, we were able to identify conclusive models. Forinstance, rs2736100 in the telomerase reverse transcript-
ase (TERT) gene was reported to exert antagonistic
effects in idiopatic pulmonary fibrosis (IPF) and testicu-
lar germ cell tumor (TGCT) and two other cancer traits
[47-53]. Whereas telomerase activity is generally upregu-
lated in tumors sustaining proliferation and potentiating
mutagenesis and transformation of cancer cells [54], in
IPF limited cell division due to decreased telomerase ac-
tivity is thought to contribute to the phenomenon of
high percentages of apoptotic cells in fibroblasts [55].
Consistent with that observation, disturbed telomerase
activity in TGCT is believed to form a distinct mechan-
ism of cancerogenesis in this tumor type [53]. This dis-
tinction from other cancer traits is believed to be based
on the fact that testicular germ cells are the only adult
cell type with high telomerase expression [56]. Another
example is the telomerase RNA component TERC,
which is essential for TERT functioning. Opposite alleles
of SNP rs10936599 are associated with CeD and colorec-
tal cancer (CRC) [35,57]. Jones et al. showed that
rs2293607, a variant tagged by rs10936599, alone is suffi-
cient to modulate TERC expression [58]. While in CRC
this leads to TERC overexpression and longer telomeres,
the opposite might apply to CeD, which exhibits telo-
mere reduction and genomic instability [58,59]. The ob-
servation that both constituents of the telomerase
complex contain independent antagonistic variants is an
intriguing finding. It suggests parallel, autonomous evo-
lution of two functionally interacting loci gone to fix-
ation at a trade-off between early cell senescence or
increased apoptosis rates (as in IPF and CeD) and
oncogenesis.
A further example is rs1393350 in the tyrosinase
(TYR) gene where the opposite alleles are linked to
vitiligo and melanoma [60,61], potentially mirroring
the inverse correlation observed for the two traits.
The phenomenon is based on the presentation of
TYR (self-) antigens on the cell surface of melano-
cytes. It is hypothesized that in vitiligo the immune
system is hypersensitive towards TYR antigens, which
are overexpressed in melanoma cells [62]. A possible
explanation may be that opposite alleles differentially
influence the antigenicity of the TYR protein, thereby
conferring protection from melanoma but susceptibil-
ity to vitiligo through immune surveillance and vice
versa.
In cases of functionally less or uncharacterized genes
and their involvement in the associated diseases, our ap-
proach can still be used to suggest potential trait-specific
effects. Antagonistic effects of rs12720356 (localized in
the TYK2 gene) in CD and psoriasis, for instance, might
point towards different patterns of cytokine signaling in
these two diseases [24,63,64]. Likewise, rs12727642 and
rs35675666, both located in the PARK7 gene and
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differential effects of oxidative stress on each trait
[25,35].
Variant-based analysis of joint and disjoint genetic
features
In this study, we identified overlapping genetic associa-
tions and their corresponding loci with analogous or
contrasting effects on different diseases. We addressed
the methodological challenges of the identification of the
functional entities affected by GWAS-detected variants.
Associations formally implicate genomic regions which
are captured via tagging SNPs representing haplotype
blocks. By using the population-specific LD-based haplo-
type data provided by the HapMap project [65,66] or,
more recently, the 1000 genomes project [67], SNP
arrays are constructed aiming at a high coverage of the
total genome variation, but without considering biologic-
ally functional aspects. The advantage of GWAS as a
method is its unbiased approach to identify genomic
regions compromised in a disease; a major drawback is
that the association of markers without knowledge of
the causal variants and their effects does not allow for a
straightforward biological interpretation.
As we show, the reliability of an automated assignment
of LD-based loci to the trait-associated variants is strongly
context-dependent. Especially in cases of high gene dens-
ity or, conversely, in intergenic regions/gene deserts, re-
solving GWAS signals is not possible without further
knowledge. Simplifications such as more basic locus as-
signment approaches which neglect the LD structure of
the genome (e.g. classifying a SNP as affecting only the
most proximal gene) may seem more intuitive, might fa-
cilitate analyses and could be useful to identify causal
disease-gene associations. These correct associations of
genes which are detected through significant enrichment
of a harbored tagging variant in a patient cohort may not
be discovered when incorporating LD data in cases where
the LD block of the respective variant spans across several
genes. However, such approaches disregard a basic
principle defining the current GWAS paradigm, namely
the use of LD information in the design of genotyping
arrays to achieve the genome-wide coverage of common
SNPs. Hence, it can be problematic to project the variant-
based GWAS data on genes or loci. Accordingly, we
decided to use variant-based methods and concentrated
on strong gene candidates identified via the gene function
of single-gene loci whenever suggesting potential bio-
logical effects of the considered variants.
In the analysis of genetic overlaps we followed the hy-
pothesis that the effects of variants shared across several
diseases correspond to the reported risk alleles. If the
risk allele is the same in all associated diseases, we as-
sume the effect to be the same, i.e. that there is acommon underlying etiology. For closely related diseases
a positive correlation is not surprising, e.g. a GWAS on
psoriatic arthritis (PSA) will also detect agonistic var-
iants such as rs33980500 that are also associated with
psoriasis (PS) [68,69]. Indeed, the vast majority of agon-
istic variants in our data set links groups of related dis-
eases and thus may mark interesting target regions for
therapeutic interventions. However, we also found a few
agonistic signals connecting apparently unrelated dis-
eases, e.g. rs6010620 which exerts susceptibility for both
glioma and atopic dermatitis (AD) [50,51,70,71]. If our
hypothesis is correct, an endophenotype influencing
both diseases may be present which has yet to be identi-
fied. For antagonistic SNPs, on the other hand, we de-
scribe plausible mechanisms that may render variants
protective against one trait and predisposing to another,
labeling the affected genes/loci as pleiotropic. If pleio-
tropic effects are as frequent as evolutionary modelers
postulate [2,72] and this effects can be identified by ana-
lyses based on GWAS, this might have great implica-
tions for the development and use of therapeutics
because it would enable avoidance of potential side
effects when targeting such loci. Already, there are more
than 50 genotype/drug interactions known for which
therapeutic dosing recommendations are available [73].
Conclusions
Our results present new starting points for studying the
genetics of complex diseases. The observation that more
than 15% of the SNPs considered in our study are asso-
ciated both agonistically and antagonistically with related
as well as unrelated disorders indicates that the molecu-
lar mechanisms influencing causes and progress of
human diseases are in part interrelated. Genetic overlaps
between two diseases also suggest the importance of the
affected entities in the specific pathogenic pathways and
should be investigated further. These may be secondary,
such as genes involved in inflammatory responses
related to T2D as well as cancer [30,38]. The findings
presented also demonstrate the need to clarify the rela-
tion of any phenotype linked to an associated marker.
For directly interrelated diseases such as PS and PSA
often PS patients without present arthritis or arthritis in
the past are used as additional control group. Associa-
tions are then interpreted as PSA-specific if not as
strongly associated with PS [74,75]. Comparable proce-
dures may proof useful in frequently co-occurring
diseases genetically linked by agonistic variants. Never-
theless, the complex genetics of multifactorial diseases
asks for a better understanding of the functions under-
lying common disorders. An improved characterization
of the endophenotype, such as metabolite or protein
concentrations, may enhance our understanding of iden-
tical pathomechanisms that link agonistic genetic loci to
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hand, that are harbored in the same locus may trigger
different mechanisms interfering with the genetic or en-
vironmental background. The detailed examination of
antagonistically associated loci may thus lead to first
insight into the mechanism of the various types of plei-
otropy in human diseases.
Methods
Association selection and curation
We obtained the core list of candidate sentinel SNPs from
‘A Catalog of Published Genome-Wide Association Stud-
ies’ [1] accessed on June 30, 2011 (http://www.genome.
gov/gwastudies). Additional associations where retrieved
from HuGE Navigator [76] and automated Text Mining
[77]. New (i.e. not contained in the GWAS Catalog) asso-
ciation markers were manually tested on compliance with
the criteria for inclusion in the GWAS Catalog beforeFigure 4 Data prioritization and analysis workflow. We
established a semi-automated curation pipeline which automatically
gathers and annotates GWA data obtained from three sources (locus
assignment included). Last step of the preprocessing was the
manual inspection of risk alleles and odds ratios. With this data set
at hand, we construct a locus-based (SLN) and a variant-based (SVN)
network representation of the data. For quality reasons, we then
limited analyses to the SVN and investigated the contained variants
and their effects further.insertion in the candidate list. Associations with copy
number variants (CNVs) as well as with pending SNPs
were removed. For consistency, SNP identifiers were
mapped to the RefSNP numbers of the same dbSNP re-
lease (build 131, http://www.ncbi.nlm.nih.gov/snp). For
the same reason we semi-automatically translated trait
descriptions to the official terms given in the Medical Sub-
ject Headings (MeSH). In this process, associations with
quantitative and non-disease traits were eliminated. Fi-
nally, we lowered the association P-value threshold from
10−5 (as in the GWAS Catalog criteria) to 10−7 as to re-
duce the potential of artificial associations. The workflow
of the methods of our approach is sketched in Figure 4.Construction of GWAS networks
For the construction of the locus-based data representa-
tion, we defined an associated locus as the whole genomic
region captured by SNPs in strong LD, r2≥ 0.8, with the
marker originally reported in a GWAS contained in our
data set. The locus is then characterized as all genes
located within this genomic region (referred to as “gene
locus”) (Figure 2). If the region contains no genes, the
locus is assigned to its chromosomal location (referred to
as “intergenic locus”). LD data and gene information were
obtained with the SNAP tool [78]. After locus assignment,
our final data set consisted of 111 different traits linked
via 1,120 SNPs to 508 gene loci and 226 intergenic loci.
Based on this list we constructed a bipartite graph
consisting of two disjoint sets of nodes (Figure 1A)
representing the complete association data. The first
node set corresponds to the traits, whereas the other set
comprises the associated loci. Two nodes are connected
by an edge if a variant within the respective locus is
associated with the corresponding trait. By removal of
isolated traits, i.e. traits which share no associated locus
with another trait (n= 27) (Figure 1A), and cutting out
loci which are associated with only one trait (n= 577),
we retrieved the SLN (Figure 1B).
To obtain a variant-based representation of the data,
we repeated the network generation on marker scale by
utilizing the set of variants associated with more than
one distinct trait. For this, we used the LD data to mutu-
ally assign the associated traits of sentinel SNPs in pair-
wise LD if not already present. In other words, each
variant is, in addition to its own associated traits,
assigned the traits associated with all correlated SNPs.
This set consists of 175 SNPs located in 94 loci and
associated with 55 diseases (Additional file 2: Table S1).
In the resulting bipartite SVN, a trait and a locus are
linked if the locus contains a variant which comprises
associations with this and at least one other trait. Here,
the allele information was included in the graph
visualization by coloring of the edges (Figure 1C). Both
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files, see Additional files 5 and 6.
Network analysis
The network concepts which we used to compare the prop-






n n 1ð Þ ¼
mean kð Þ
n 1 ð1Þ
where aij=1 if nodes i and j are connected and 0 otherwise.
mean(k) denotes the mean connectivity, which for a node i












mean kð Þ ð3Þ
To automatically distinguish the two node sets con-
tained in the SVN, we used directed edges. Direction is
always from disease (source) to locus (target). The dis-
tinct node degree distributions thus are identical to the
indegree distribution and the outdegree distribution.
The topological coefficient as a measure of modularity
[80] Ti of a node i is defined as:
Ti ¼
0; if Ni < 2
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where Ni is the number of neighbors of i and S(i, j) is
the number of shared neighbors of nodes i and j (un-
defined if i and j do not share a neighbor) plus one if j is
a neighbor of i.
Power-law functions of the form y= eaxb were fitted
using least squares fitting where the coefficients are
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BB@for the linear transformation of the power-law functions,
i.e. ln y= a+ b ln x.Determination of agonistic and antagonistic effects
For all variants associated with more than one trait,
we manually extracted the risk alleles (OR> 1, independ-
ently of major or minor allele status) and odds ratios
from the reporting studies. The alleles were mapped to
the forward DNA strand according to dbSNP 131. The
same procedure was applied to markers which were in-
directly associated with a trait over LD. If for all traits
the same associated risk allele (and corresponding al-
lele, respectively) was reported, the SNP was classified
as agonistic. If the risk alleles of a SNP were opposed
in the associated diseases, the variant was classified as
antagonistic.Genetic clustering
We applied complete-linkage hierarchical clustering to
identify groups of traits genetically overlapping with re-
spect to agonistic signals. Normalization was performed
using the linear PCC defined as ρX;Y ¼ cov X;Yð ÞσXσY where
the input are the vectors of the variant-based agonis-
tic overlap of two distinct diseases X and Y to all
other diseases. Thus, disorders which are clustered to-
gether show a homogeneous association overlap pat-
tern to all other diseases, while diseases which are
not clearly assigned to a cluster present a more het-
erogeneous pattern relatively unique in the SNP data.
For cluster definition, we used a Euclidian distance
threshold of 1.71. This threshold was determined
as the maximal distance at which the six traits
not correlating with other diseases (Figure 3) remain
non-clustered.Calculation of the CPMA statistic for autoimmune loci
We downloaded the dataset S1 from [8] and extracted
the information on autoimmune-linked SNPs contained
in the SVN. We used the Z-scores given in the file to
compute two-sided P-values for all seven GWAS. Using
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P-values as described in [8].Additional files
Additional file 1: Figure S1. Disease-centric projection of the SVN. The
SVN (see Figure 1C) is transformed in a network consisting of diseases
only. Here, two traits are connected if they are associated with the same
variant. The colors of the disease nodes correspond to disease classes
according to the MeSH ontology, multi-colored nodes indicate an
association with different disease classes. The node size reflects the
number of traits a disease has shared associations with. The direction of
the shared variants is indicated by the edge color reflecting the
corresponding allelic information: gray indicates agonistic variant(s), red
corresponds to antagonistic variant(s), and blue mark both agonistic and
antagonistic signals in the two corresponding traits.
Additional file 2: Table S1. List of all disease-variant associations
contained in the SVN. Contained is the high-quality data set which was
used for the construction of the SVN, ordered by the rs-number of the
tagging SNP. The first column contains this rs-number of the tagging
SNP, the second column lists the disease associations and the third
column gives the PubMed ID of the GWAS publication the association
was reported in. In the fourth column the (gene or intergenic) locus of
the tagging SNP can be found. The sixth column gives the SNP and the
risk allele reported in the GWAS. If the rs-numbers of the tagging SNP
(column 1) diverges from the rs-number listed here, the association was
assigned via LD. For these cases, in column seven the corresponding
allele of the tagging SNP is given, followed by the P-value and the odds
ratio reported with the SNP (i.e. the reported SNP in column six). Blue
row-coloring identifies non-HLA located antagonistic SNPs, while rows
containing agonistic SNPs are not colored. Rows in green list antagonistic
SNPs in the HLA region (not considered in the manuscript). Tagging SNPs
which we included in our rationale are marked in bold red font.
Additional file 3: Table S2. CPMA P-values for autoimmune-linked
SNPs and their corresponding loci in the SVN. Listed are all SNPs
contained in Supplementary Table 1 for which association data could be
obtained from [8]. The second column gives the LD-based loci of the
SNPs as used in the SVN. The third column contains the CPMA P-Values.
Additional file 4: Figure S2. Network properties of the SVN. A: The
log-log-plot of the degree distribution of the SVN follows a power-law
(γ= 1.32; R2 = 0.69) and therefore attributes the SVN to be scale-free and,
thus, non-random. B: The modular structure of the SVN was confirmed by
the topological coefficient which follows a power-law distribution on a
log-log-scale. When considering the two node types separately, in both
cases a scale-free topology can be identified: C: disease nodes (γ= 0.97;
R2 = 0.71) and D: locus nodes (γ= 2.98; R2 = 0.93).
Additional file 5: Graph data of the SLN in yEd graphml format.
View with yEd (http://www.yworks.com/en/products_yed_about.html).
Using yEd, the file can be converted to GML format which is readable by
Cytoscape (http://www.cytoscape.org/).
Additional file 6: Graph data of the SVN in yEd graphml format.
View with yEd (http://www.yworks.com/en/products_yed_about.html).
Using yEd, the file can be converted to GML format which is readable by
Cytoscape (http://www.cytoscape.org/).Competing interests
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